Catalyst
Slingshot members are tracking this event:
Paratek (PRTK) aiming to commence enrollment in proof-of-concept cUTI Phase 2 study evaluating Antibiotic Omadacycline in the fourth quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 03, 2018
Occurred Source:
http://investor.paratekpharma.com/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2324587
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Omadacycline, Proof-of-concept, Phase 2
